These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; 63/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer’s Disease Patients; 63/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer’s Disease; 63/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric tau and soluble tau aggregates. This evidence concerns the gene MAPT and tauopathy.